Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 306

1.

The importance of anti-insulin antibody in patients with type 1 diabetes mellitus treated with continuous subcutaneous insulin infusion or multiple daily insulin injections therapy.

Sahin SB, Cetinkalp S, Ozgen AG, Saygili F, Yilmaz C.

Acta Diabetol. 2010 Dec;47(4):325-30. doi: 10.1007/s00592-010-0221-5. Epub 2010 Sep 15.

PMID:
20842389
2.

Comparison of continuous subcutaneous insulin infusion (CSII) and multiple daily injections (MDI) in paediatric Type 1 diabetes: a multicentre matched-pair cohort analysis over 3 years.

Jakisch BI, Wagner VM, Heidtmann B, Lepler R, Holterhus PM, Kapellen TM, Vogel C, Rosenbauer J, Holl RW; German/Austrian DPV Initiative and Working Group for Paediatric Pump Therapy.

Diabet Med. 2008 Jan;25(1):80-5. doi: 10.1111/j.1464-5491.2007.02311.x.

PMID:
18199134
3.
5.

Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH-based multiple daily insulin injections (MDI) on glycaemic control and quality of life: results of the 5-nations trial.

Hoogma RP, Hammond PJ, Gomis R, Kerr D, Bruttomesso D, Bouter KP, Wiefels KJ, de la Calle H, Schweitzer DH, Pfohl M, Torlone E, Krinelke LG, Bolli GB; 5-Nations Study Group.

Diabet Med. 2006 Feb;23(2):141-7.

PMID:
16433711
6.

In Type 1 diabetic patients with good glycaemic control, blood glucose variability is lower during continuous subcutaneous insulin infusion than during multiple daily injections with insulin glargine.

Bruttomesso D, Crazzolara D, Maran A, Costa S, Dal Pos M, Girelli A, Lepore G, Aragona M, Iori E, Valentini U, Del Prato S, Tiengo A, Buhr A, Trevisan R, Baritussio A.

Diabet Med. 2008 Mar;25(3):326-32. doi: 10.1111/j.1464-5491.2007.02365.x.

PMID:
18307459
8.
11.

A clinical trial of continuous subcutaneous insulin infusion versus multiple daily injections in older adults with type 2 diabetes.

Herman WH, Ilag LL, Johnson SL, Martin CL, Sinding J, Al Harthi A, Plunkett CD, LaPorte FB, Burke R, Brown MB, Halter JB, Raskin P.

Diabetes Care. 2005 Jul;28(7):1568-73.

PMID:
15983302
13.

A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine.

Doyle EA, Weinzimer SA, Steffen AT, Ahern JA, Vincent M, Tamborlane WV.

Diabetes Care. 2004 Jul;27(7):1554-8.

PMID:
15220227
14.

Benefits of continuous subcutaneous insulin infusion in type 1 diabetes previously treated with multiple daily injections with once-daily glargine and pre-meal analogues.

Torres I, Ortego J, Valencia I, García-Palacios MV, Aguilar-Diosdado M.

Exp Clin Endocrinol Diabetes. 2009 Sep;117(8):378-85. doi: 10.1055/s-0029-1225337. Epub 2009 Jul 23.

PMID:
19629931
15.
16.
17.

A comparison of glycaemic variability in CSII vs. MDI treated type 1 diabetic patients using CGMS.

Simon B, Treat V, Marco C, Rosenberg D, Joseph J, Hipszer B, Li Y, Chervoneva I, Padron-Massara L, Jabbour S.

Int J Clin Pract. 2008 Dec;62(12):1858-63. doi: 10.1111/j.1742-1241.2008.01932.x.

PMID:
19166434
18.
19.

Metabolic control in children with diabetes mellitus who are younger than 6 years at diagnosis: continuous subcutaneous insulin infusion as a first line treatment?

Sulmont V, Souchon PF, Gouillard-Darnaud C, Fartura A, Salmon-Musial AS, Lambrecht E, Mauran P, Abely M.

J Pediatr. 2010 Jul;157(1):103-7. doi: 10.1016/j.jpeds.2009.12.034. Epub 2010 Mar 15.

PMID:
20227730
20.

Supplemental Content

Support Center